First-line Patients with Erythrodermic First-line treatment of CTCL with MF/SS (stage MF/SS with in first, therapy for population MF stage III and major criteria III/IVA/B1/0), the following second or for first-line of: with a strength of criteria: third line CTCL treatment of SS recommendation therapy in patients (strength of and stage of B. stage IIB-IV (stage IIIA or III or IVA MF or SS IIIB). of C) CTCL and diagnosis of patients while Also minor CTCL, noting that recommended Early-stage criteria: evidence of ECP is more TSEB + ECP and disease circulating circulating effective in SS IFN-α + ECP (stage IA, IB, clonal clonal patients. combination IIA) disease, disease and treatments considered evidence of evidence of only for circulating circulating clinical trial Sézary cells Sézary cells purposes (>10% of (10% of circulating lymphocytes • Stage IVA1 present). (i.e. patients CD4/CD8 with B2 ratio >10. score) and a T score of T1, T2 or T4. • Stage IVA2 (i.e. patients with N3 score) and a T score of T4.
population First-line treatment of MF stage III and for first-line treatment of SS (strength of of C) Patients with CTCL with major criteria of: and stage III or IVA CTCL and minor criteria: circulating clonal disease, evidence of circulating Sézary cells (>10% of circulating CD4/CD8 ratio >10. Erythrodermic MF/SS (stage III/IVA/B1/0), with a strength of recommendation of B. Also recommended TSEB + ECP and IFN-α + ECP combination treatments MF/SS with the following criteria: diagnosis of CTCL, evidence of circulating clonal disease and evidence of circulating Sézary cells (10% of lymphocytes present). in first, second or third line therapy in stage IIB-IV MF or SS patients while noting that ECP is more effective in SS patients. First-line therapy for CTCL patients (stage IIIA or IIIB). Early-stage disease (stage IA, IB, IIA) considered only for clinical trial purposes • Stage IVA1 (i.e. patients with B2 score) and a T score of T1, T2 or T4. • Stage IVA2 (i.e. patients with N3 score) and a T score of T4.
1420%20-%20CTCL%20-%20Final%20Protocol%20v2.docx